PARIS--(BUSINESS WIRE)--Regulatory News:
IntegraGen (Paris:ALINT) (FR0010908723 - ALINT), IntegraGen, a company specializing in the transformation of data from biological samples to actionable genomic information and developer of diagnostic tools for oncology, today announced its revenue for the first half of 2016. The company reported strong growth for its clinical research and microbiology genomics businesses and stability in its genomic services business for research activities with a significant increase in orders across all genomic activities.
Total revenue for all IntegraGen businesses for the first half of 2016 was €2.9 million. This represents a 10% increase compared to same time period in 2015. Revenue for genomic services performed for "research" customers remained stable, amounting to € 2.1 million during this time period. Revenue for clinical research-related genomic services in Villejuif, France at IntegraGen’s lab on the site of Gustave Roussy and microbiology-related genomic services at the Pasteur Institute increased sharply totaling €0.8 million during the first half of 2016.
In parallel with the above, new orders, which significantly increased over 15% in the first half of last year, recorded a 9% increase compared to the same time period in 2015.
Many operational and scientific advances
In the first half of 2016 the company made two major announcements. This included presentation of clinical data associated with the company’s miR-31-3p biomarker from an analysis of tumor samples from patients enrolled in the FIRE-3 study during the 2016 American Society of Oncology (ASCO) meeting held in Chicago. This international meeting is the largest gathering of clinicians and researchers involved in the care and treatment of cancer patients. The data IntegraGen presented at ASCO confirmed the predictive value of the miR-31-3p biomarker and reinforced the ability of the biomarker to identify metastatic colorectal cancer patients who would clinically benefit from targeted therapeutic treatment. The Greater Paris University Hospitals (AP-HP) and IntegraGen also recently announced a strategic partnership for the development of a high-throughput sequencing platform covering all research and clinical research institutions associated with AP-HP.
"The double-digit growth in sales IntegraGen achieved during the first half of 2016 reflects the accelerated deployment our clinical research and microbiology services, which will be augmented in the next few months by the placement of an additional clinical research sequencing platform with AP-HP,” stated Dr. Bernard Courtieu, IntegraGen’s Managing Chairman and CEO. “These results confirm the strength of our business model and highlights the quality and relevance of our scientific strategy and the effectiveness of our sales and operations efforts. With this momentum, we are confident in the future prospects for the company".
IntegraGen will publish its half year results on October 12, 2016.
IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2015, IntegraGen had 37 employees and had generated revenue of €5.6 million in 2015. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).
For more information on IntegraGen visit www.integragen.com.